CRP and COVID-19: Neither symptoms nor conventional clinical laboratory measurements (serum C-reactive protein (CRP), blood D-dimers etc.)have sufficient prognostic power and, thus, approved interventions for severe COVID-19 (including systemic corticosteroids and tocilizumab) are administered broadly to patients admitted to the ICU as clinicians lack the tools to identify accurately patients at risk of long-term complications and death (11–15).